Pathologic assessment of esophageal squamous cell carcinoma after neoadjuvant immunotherapy
10.3760/cma.j.cn115610-20230210-00056
- VernacularTitle:食管鳞状细胞癌新辅助免疫治疗后病理学评估
- Author:
Yingyong HOU
1
;
Dongxian JIANG
;
Lijie TAN
Author Information
1. 复旦大学附属中山医院病理科，上海 200032
- Keywords:
Esophageal neoplasms;
Squamous cell carcinoma;
Neoadjuvant immuno-therapy;
Efficacy;
Pathologic assessment
- From:
Chinese Journal of Digestive Surgery
2023;22(3):316-321
- CountryChina
- Language:Chinese
-
Abstract:
For locally advanced esophageal squamous cell carcinoma (ESCC), neoadjuvant therapy combined with surgery has become the standard treatment schedule. The application of immunotherapy, represented by programmed death-1 and programmed death-ligand 1 inhibitors, has injected new vitality into neoadjuvant therapy for ESCC. At present, a large number of clinical trials are being carried out and explored, which brings new challenges to the diagnosis of clinical pathologists. Combined with the latest researches at home and abroad and clinical diagnosis problems, the authors summarize the relevant problems and progress of pathological evaluation before and after neoadjuvant immunotherapy from the perspective of pathology, in order to improve the level of clinical pathological diagnosis and provide reference for further optimizing the comprehensive treat-ment strategy.
